Orchestra BioMed Holdings Inc [OBIO] stock prices are up 11.60% to $3.56 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The OBIO shares have gain 30.40% over the last week, with a monthly amount glided 36.92%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Orchestra BioMed Holdings Inc [NASDAQ: OBIO] stock has seen the most recent analyst activity on August 20, 2025, when BTIG Research downgraded its rating to a Neutral. Previously, BTIG Research started tracking the stock with Buy rating on March 20, 2025, and set its price target to $12. On January 02, 2025, Barclays initiated with a Overweight rating and assigned a price target of $16 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $14 on August 22, 2024. B. Riley Securities initiated its recommendation with a Buy and recommended $15 as its price target on July 25, 2024. Jefferies started tracking with a Buy rating for this stock on January 19, 2024, and assigned it a price target of $14. In a note dated February 24, 2023, Piper Sandler initiated an Overweight rating and provided a target price of $15 on this stock.
The stock price of Orchestra BioMed Holdings Inc [OBIO] has been fluctuating between $2.20 and $6.50 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Orchestra BioMed Holdings Inc [NASDAQ: OBIO] shares were valued at $3.56 at the most recent close of the market. An investor can expect a potential return of 237.08% based on the average OBIO price forecast.
Analyzing the OBIO fundamentals
The Orchestra BioMed Holdings Inc [NASDAQ:OBIO] reported sales of 2.94M for trailing twelve months, representing a surge of 7.46%. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -24.21%, Pretax Profit Margin comes in at -23.67%, and Net Profit Margin reading is -23.67%. To continue investigating profitability, this company’s Return on Assets is posted at -1.63, Equity is -2.89 and Total Capital is -2.77. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 6.68.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Orchestra BioMed Holdings Inc [NASDAQ:OBIO]’s Current Ratio is 2.10. On the other hand, the Quick Ratio is 2.09, and the Cash Ratio is 1.1. Considering the valuation of this stock, the price to sales ratio is 65.33, the price to book ratio is 466.58.
Transactions by insiders
Recent insider trading involved Aryeh Jason, Director, that happened on Sep 19 ’25 when 1000.0 shares were purchased. Director, Fain Eric S completed a deal on Aug 25 ’25 to buy 5760.0 shares. Meanwhile, Sherman Darren bought 3000.0 shares on Aug 25 ’25.
